Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation

BMC Psychiatry

John M. Kane²  Josephine Cucchiaro³  Jane Xu³  Christoph U. Correll²  Leslie Citrome¹  Antony Loebel³ 

[1] ᅟ, 11 Medical Park Drive, Suite 106, Pomona 10970, NY, USA;The Zucker Hillside Hospital, Glen Oaks, and the Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA;Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA

关键词: Study design;    Schizophrenia;    Lurasidone;    Early responder;    Dosing;    Antipsychotic;   

Others  :  1231555
DOI  :  10.1186/s12888-015-0629-0

 received in 2015-06-17, accepted in 2015-10-02,  发布年份 2015

【 摘 要 】

Background

Early non-response to antipsychotic treatment in patients with schizophrenia has been shown in multiple studies to predict poor response at short-term trial endpoint. Therefore, strategies to address the challenge of non-improvement early in the course of treatment are needed. A novel trial design was developed to assess the potential utility of antipsychotic dose escalation in patients with an inadequate initial treatment response. This design was embedded in a study intended to assess the efficacy of low dose lurasidone in patients with schizophrenia. The purpose of this report is to describe the background, rationale and design of this study that included a novel method for the assessment of the potential for dose–response in early non-responding patients with schizophrenia.

Methods/Design

In this 6-week, international, multicenter, double-blind trial, eligible adults with acute schizophrenia were randomized to receive fixed doses of lurasidone 20 mg/day, 80 mg/day (active control), or placebo in a 1:2:1 ratio. Patients initially randomized to lurasidone 80 mg/day who did not have a Positive and Negative Syndrome Scale total score improvement ≥20 % at Week 2 were re-randomized on a 1:1 basis to receive either lurasidone 80 mg/day or lurasidone 160 mg/day for the remainder of the trial. All other groups remained on their initially assigned treatment. The formal primary objective of the study was to evaluate the efficacy of low-dose lurasidone (20 mg/day) compared to placebo; secondary objectives included evaluating the efficacy of lurasidone 80 mg/day versus 160 mg/day in early non-responders, and evaluating the efficacy of lurasidone in all subjects initially randomized to 80 mg/day versus placebo.

Discussion

Since a lack of early improvement predicts poor response to short-term antipsychotic treatment in patients with schizophrenia, several treatment strategies have been proposed to enhance treatment outcome in early non-responders. A novel clinical trial design involving a placebo arm and re-randomization of early non-responders to increased or maintained antipsychotic dose was developed. The study design described in this report provides a robust method to assess the value of antipsychotic dose escalation in patients with schizophrenia who demonstrate poor initial treatment response.

Trial registration

ClinicalTrials.gov NCT01821378; initial registration March 22, 2013

【 授权许可】

   
2015 Loebel et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, et al.: Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 2008, 102:230-40.
• [2]Agid O, Kapur S, Arenovich T, Zipursky RB: Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003, 60:1228-35.
• [3]Leucht S, Busch R, Hamann J, Kissling W, Kane JM: Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 2005, 57:1543-9.
• [4]Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM: Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2013, 160:2063-5.
• [5]Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, et al.: Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010, 35:581-90.
• [6]Correll CU, Pikalov A, Hsu J, Cucchiaro J, Goldman R, Loebel A. Early improvement predicts endpoint response to lurasidone in schizophrenia: pooled analysis of five double-blind trials. Poster presentation. American Psychiatric Association, May 3–7, 2014, New York, NY
• [7]Hatta K, Ito H: Strategies for Early Non-response to Antipsychotic Drugs in the Treatment of Acute-phase Schizophrenia. Clin Psychopharmacol Neurosci 2014, 12:1-7.
• [8]Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, et al.: Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 1993, 29:309-14.
• [9]Lindenmayer JP, Citrome L, Khan A, Kaushik S, Kaushik S: A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 2011, 31:160-8.
• [10]Honer WG, MacEwan GW, Gendron A, Stip E, Labelle A, Williams R, et al.: A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry 2012, 73:13-20.
• [11]Goff DC, McEvoy JP, Citrome L, Mech AW, Bustillo JR, Gil R, et al.: High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J Clin Psychopharmacol 2013, 33:485-90.
• [12]Latuda: US Package Insert. 2013. [http://www.latuda.com/LatudaPrescribingInformation.pdf]. Accessed October 12, 2015.
• [13]Latuda: EU Summary of Product Characteristics. 2014. [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002713/WC500164683.pdf]. Accessed October 12, 2015.
• [14]Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, et al.: Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res 2013, 145:101-9.
• [15]Chapel S, Chiu YY, Hsu J, Xu J, Cucchiaro, Loebel A. Dose–response model of lurasidone treatment in schizophrenia. Poster presentation. American Psychiatric Association, May 5–9, 2012, Philadelphia, PA
• [16]US Food and Drug Administration: NDA Approval letter. [http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/200603s000ltr.pdf]. Accessed October 12, 2015.
• [17]Vermeiden M, Kamperman AM, Vulink ME, van den Broek WW, Birkenhäger TK: Early improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatients. Psychopharmacology (Berl) 2015, 232:1347-56.
• [18]Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME: Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 2009, 70:344-53.
• [19]Kemp DE, Johnson E, Wang WV, Tohen M, Calabrese JR: Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. J Clin Psychiatry 2011, 72:1236-41.
• [20]Correll CU, Kishimoto T, Kane JM: Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues Clin Neurosci 2011, 13:155-72.
• [21]Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, et al.: Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol 2008, 28:392-400.
• [22]Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, et al.: Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study. Eur Psychiatry 2009, 24:501-6.